Axsome Therapeutics Stock Dives On Mixed Results In Alzheimer's ...

Dec 30, 2024 · Axsome stock skidded 2.2% to close at 84.78. Shares were already below their 50-day line, but made a definitive drop below their 200-day moving average at the open. …

2%
OFF

Axsome Therapeutics Stock Dives On Mixed Results In Alzheimer's ...

2 weeks from now

Dec 30, 2024 · Axsome stock skidded 2.2% to close at 84.78. Shares were already below their 50-day line, but made a definitive drop below their 200-day moving average at the open. …

investors.com

11%
OFF

Axsome Therapeutics Stock Tumbles As Alzheimer's Studies Reveal …

2 weeks from now

Dec 30, 2024 · Shares of Axsome Therapeutics (AXSM) fell over 11% in Monday morning trade after it posted mixed results of its Alzheimer’s study. The New York-based biopharmaceutical …

stocktwits.com

2%
OFF

Axsome Flashes A Bearish Signal On Mixed Results In Alzheimer's …

2 weeks from now

Axsome stock skidded 2.2% to close at 84.78. Shares were already below their 50-day line, but made a definitive drop below their 200-day moving average at the open. Shares later retook …

msn.com

12%
OFF

Axsome Reports Mixed Results For Alzheimer's Agitation Drug - MSN

2 weeks from now

Axsome Therapeutics (NASDAQ:AXSM) stock fell 12% Monday after the company reported mixed Phase 3 results for its drug AXS-05, or dextromethorphan-bupropion, in the treatment of …

msn.com

12%
OFF

Axsome Therapeutics Stock Slips 12% On Mixed Results On …

2 weeks from now

Dec 30, 2024 · Shares of Axsome Therapeutics, Inc. slipped nearly 12% on Monday morning after the company announced results of phase 3 clinical program of AXS-05 in Alzheimer's disease …

rttnews.com

12%
OFF

Axsome Reports Mixed Results For Alzheimer's Agitation Drug

2 weeks from now

Dec 30, 2024 · Axsome Therapeutics (AXSM) stock fell 12% Monday after the company reported mixed Phase 3 results for its drug AXS-05 in the treatment of agitation in Alzheimer's disease …

seekingalpha.com

$131.53
OFF

Truist Securities Raises Price Target On Axsome Therapeutics To …

2 weeks from now

5 days ago · -- Axsome Therapeutics has an average rating of buy and mean price target of $131.53, according to analysts polled by FactSet. ... Axsome Therapeutics Mixed Alzheimer's …

marketscreener.com

9%
OFF

Biotech Stocks Put Up A Mixed Showing At JPM; BridgeBio, …

2 weeks from now

1 day ago · While Cartesian Therapeutics ramped 8.9% to 18.33 on a series of updates, biotech stocks Beam Therapeutics and SpringWorks Therapeutics fell on their announcements and …

investors.com

$92
OFF

Axsome Therapeutics Provides Preliminary Fourth Quarter And Full …

2 weeks from now

2 days ago · Auvelity preliminary 4Q and full year 2024 net product sales of $92.6 million and $291.4 million, respectively Sunosi preliminary 4Q and full year 2024 net product revenue of …

businessinsider.com

FAQs about Axsome Therapeutics Stock Dives On Mixed Results In Alzheimer's ... Coupon?

Does Axsome Therapeutics have Alzheimer's disease agitation?

Shares of Axsome Therapeutics dropped Monday on mixed test results for its Alzheimer's disease agitation treatment. Please watch the video at Investors.com - How To Sell Stocks: When To Cut Losses Agitation is a common symptom of Alzheimer's disease which can cause a patient to feel restless, worried and unable to settle down. ...

Why did Alpha Axsome Therapeutics (axsm) stock fall 12% Monday?

Market Data Sources © 2025 Seeking Alpha Axsome Therapeutics (AXSM) stock fell 12% Monday after the company reported mixed Phase 3 results for its drug AXS-05 in the treatment of agitation in Alzheimer's disease patients. ...

Why did xsome Therapeutics stock fall 12% Monday?

A xsome Therapeutics (NASDAQ: AXSM) stock fell 12% Monday after the company reported mixed Phase 3 results for its drug AXS-05, or dextromethorphan-bupropion, in the treatment of agitation in Alzheimer's disease patients. ...

Is Axsome Therapeutics (axsm) a good stock to buy?

Axsome Therapeutics is based in New York City and develops central nervous system [CNS] therapies. Since my last analysisin May 2024, the stock has appreciated by roughly 14.34%. However, recently, AXSM stock has pulled back following mixed results for the clinical trial of AXS-05, an Alzheimer’s disease agitation drug. ...

Why did ivelinradkov Axsome Therapeutics stock fall 12%?

Play(1min) IvelinRadkov Axsome Therapeutics (NASDAQ:AXSM) stock fell 12% Monday after the company reported mixed Phase 3 results for its drug AXS-05, or dextromethorphan-bupropion, in the treatment of agitation in Alzheimer's disease patients. ...

Why is Axsome Therapeutics (axsm) under pressure?

Shares of Axsome Therapeutics (AXSM) are under pressure on Monday after the company reported mixed results for a pair of studies of its Alzheimer’s agitation drug. ...